Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-09-15, Stock:NVS, The news for the past five days is as follows:
2020-09-08: NEWS1: Novartis (NVS) Releases Positive Data on Enerzair Breezhaler.NEWS2: Understanding Novartis's Unusual Options Activity.NEWS3: Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum.
2020-09-09: NEWS1: Roche studies Ocrevus, experimental drug in MS as Novartis moves in.
2020-09-10: nan
2020-09-11: NEWS1: Analyst Report: Novartis AG.NEWS2: Where COVID-19 vaccines stand following AstraZeneca setback.NEWS3: Novartis Stock Should Rise 20%, Analyst Says.NEWS4: Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS).NEWS5: Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis.
2020-09-14: NEWS1: Novartis Reports Positive Data on Beovu for DME Indication.NEWS2: European Medicines Agency Approves Safety Label Update For Novartis' Beovu - Quick Facts .NEWS3: European Medicines Agency (EMA) approves safety label update for Novartis Beovu®.NEWS4: Novartis aims to expand Beovu use after safety fears hurt launch.NEWS5: Novartis says Beovu matched rival Eylea in visual acuity in eye disease.NEWS6: Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME).

Answer: Rise